论文部分内容阅读
目的:探讨尼莫地平联合神经节苷脂治疗脑出血的疗效及对血清抵抗素、氧化型低密度脂蛋白（ox-LDL）表达的影响。方法:选择2018年2月至2020年2月山东省淄博市中心医院收治的100例脑出血患者，按随机数字表法分为单一治疗组与联合治疗组，每组50例。单一治疗组在常规治疗的基础上给予尼莫地平治疗，联合治疗组在常规治疗的基础上给予尼莫地平联合神经节苷脂治疗。治疗2周后评价两组的疗效，比较两组治疗前后神经功能缺损量表（NIHSS）评分、日常生活能力（ADL）评分、血清炎性反应因子、抵抗素及ox-LDL水平。结果:联合治疗组治疗总有效率高于单一治疗组[90.0%（45/50）比74.0%（37/50）]，差异有统计学意义（n P<0.05）。两组治疗后NIHSS评分均下降，ADL评分均上升，且联合治疗组治疗后NIHSS评分低于单一治疗组[（9.41 ± 1.27）分比（12.10 ± 1.65）分]，ADL评分高于单一治疗组[（67.82 ± 9.04）分比（59.10 ± 8.75）分]，差异均有统计学意义（n P<0.05）。两组治疗后血清超敏C-反应蛋白、白细胞介素-6、肿瘤坏死因子-α、抵抗素及ox-LDL水平均明显下降，且联合治疗组治疗后上述指标均低于单一治疗组[（4.81 ± 1.03）mg/L比（6.10 ± 1.73）mg/L、（40.96 ± 9.21）μg/L比（56.74 ± 8.93）μg/L、（33.20 ± 7.96）μg/L比（44.76 ± 8.43）μg/L、（0.29 ± 0.09）μg/L比（0.45 ± 0.13）μg/L、（336.25 ± 69.74）mg/L比（372.18 ± 68.52）mg/L]，差异均有统计学意义（n P0.05）。n 结论:尼莫地平联合神经节苷脂治疗脑出血疗效明确，能有效抑制炎性反应指标，降低血清抵抗素、ox-LDL水平，促进神经功能缺损恢复，提高患者生活能力。“,”Objective:To explore the efficacy of nimodipine combined with ganglioside in the treatment of cerebral hemorrhage and its effect on the expression of serum resistin and oxidized low-density lipoprotein (ox-LDL).Methods:According to the random number table method, 100 patients with cerebral hemorrhage admitted in Central Hospital of Zibo from February 2018 to February 2020 were divided into the single treatment group and the combined treatment group, with 50 cases in each group. In addition to conventional treatment, the single treatment group was additionally treated with nimodipine, and the combined group was additionally treated with nimodipine combined with ganglioside. After 2 weeks of intervention, the efficacy of the two groups was evaluated, and the National Institutes of Health Stroke Scale (NIHSS) scores, Ability of Daily Living (ADL) scores, serum inflammatory factors, resistin and ox-LDL levels were evaluated and recorded between the two groups before and after treatment.Results:The total effective rate of treatment in the combined treatment group was higher than that in the single treatment group: 90.0%(45/50) vs. 74.0%(37/50), and the difference was statistically difference (n P<0.05). After 2 weeks′ treatment, the scores of NIHSS was decreased and the scores of ADL was increased in two groups, and the scores of NIHSS in combined treatment group was lower than that in the single treatment group: (9.41 ± 1.27) scores vs. (12.10 ± 1.65) scores; the scores of ADL in the combined treatment group was higher than that in the single treatment group: (67.82 ± 9.04) scores vs. (59.10 ± 8.75) scores, and the differences were statistically differences (n P<0.05). After 2 weeks′ treatment, the levels of serum high-sensitivity C-reactive protein (hs-CRP), interleukin-6(IL-6), tumor necrosis factor-α(TNF-α), resistin and ox-LDL in the two groups were decreased, and the levels of above index in the combined treatment group were lower than those in the single treatment group: (4.81 ± 1.03) mg/L vs. (6.10 ± 1.73) mg/L, (40.96 ± 9.21) μg/L vs. (56.74 ± 8.93) μg/L, (33.20 ± 7.96) μg/L vs. (44.76 ± 8.43) μg/L, (0.29 ± 0.09) μg/L vs. (0.45 ± 0.13) μg/L, (336.25 ± 69.74) mg/L vs. (372.18 ± 68.52) mg/L, and the differences were statistically differences (n P<0.05). There was no significant difference in adverse reactions between the two groups (n P<0.05).n Conclusions:Nimodipine combined with ganglioside has a clear efficacy in the treatment of cerebral hemorrhage. It can effectively inhibit inflammation indicators, reduce serum resistin and ox-LDL levels, promote the recovery of nerve defects, and improve their living ability.